Aevum Zenth › Divisions › Life Sciences

Advancing Human Health Through Breakthrough Innovation

Zenth Life Sciences pioneers next-generation therapeutics, precision genomics, AI-driven diagnostics, and regenerative medicine. Our integrated research ecosystem accelerates discoveries from bench to bedside, extending healthy human lifespan and eradicating complex diseases.

47Active Pipelines
12FDA Approvals
$4.2BAnnual R&D
8,400+Scientists & Clinicians
Core Platforms

Integrated Research Ecosystem

Five specialized divisions converging computational power, biological insight, and clinical excellence.

💊
Molecular Therapeutics
High-throughput screening and AI-accelerated drug discovery targeting oncology, neurodegeneration, and autoimmune disorders.
Small MoleculeBiologicsADCs
🧬
Genomics & Gene Editing
CRISPR-based therapies, base editing, and whole-genome sequencing pipelines for rare diseases and precision medicine.
CRISPR-CasRNAiWGS
🤖
AI Diagnostics & Digital Health
FDA-cleared AI imaging, wearable biosensors, and predictive health algorithms integrated into clinical workflows.
Radiology AIPathologymHealth
🫀
Regenerative Medicine
Stem cell therapies, organoid modeling, and tissue engineering solutions for cardiac, neural, and musculoskeletal repair.
iPSCBiomaterialsBioprinting
🔬
Medical Devices & Robotics
Minimally invasive surgical systems, micro-robotic drug delivery, and next-gen prosthetics with neural interfaces.
Surgical RoboticsBiosensorsNeural Link
🌍
Global Clinical Network
Decentralized trial infrastructure, patient recruitment AI, and real-world evidence generation across 40+ countries.
DCTRWEMulti-Regional
Clinical Pipeline

Therapeutics in Development

Tracking breakthrough candidates across early discovery to regulatory submission.

Phase III

ZENTH-4092 (Oncology)

First-in-class BCL-2 inhibitor for relapsed/refractory CLL

2026
Phase II

ZENTH-7711 (Neurology)

Monoclonal antibody targeting tau protein aggregation in AD

2028
Phase I

ZENTH-9904 (Genetics)

AAV-mediated gene therapy for Duchenne Muscular Dystrophy

2030
FDA Submission

ZENTH-3380 (Cardiology)

Novel PCSK9 modulator for familial hypercholesterolemia

2025
Phase II

ZENTH-5520 (Immunology)

Bi-specific T-cell engager for autoimmune rheumatoid arthritis

2027
Research Infrastructure

Global Discovery Network

State-of-the-art laboratories, GMP manufacturing, and clinical sites spanning three continents.

🇺🇸Cambridge, MA
Zenth BioHub Americas
Flagship R&D campus featuring wet labs, AI compute clusters, and early-phase clinical units.
🇨🇭Zurich, CH
Genomics Institute
Next-gen sequencing hub, CRISPR validation center, and collaborative European clinical trial coordination.
🇯🇵Tokyo, JP
Medical Robotics Lab
Prototyping facility for micro-robotics, neural interfaces, and automated surgical simulation.
🇧🇪Antwerp, BE
GMP Manufacturing
ISO-certified biopharma production plant specializing in biologics, vaccines, and gene therapy vectors.
Executive Team

Scientific & Operational Leadership

Guided by Nobel laureates, former FDA advisors, and industry pioneers.

👩‍⚕️
Dr. Elena Rostova
Chief Executive Officer
Former VP at Genentech. 20+ years in biotech commercialization and translational medicine.
👨‍🔬
Dr. Aris Thorne
Chief Scientific Officer
Pioneer in AI-driven protein folding. Published 140+ peer-reviewed papers in cell biology.
👩‍💼
Sarah Chen
Head of Clinical Operations
Scaled 15 global Phase III trials. Expert in decentralized clinical trial architecture.
👨‍💻
Dr. Marcus Vance
Director of Digital Health
Architect of Zenth's AI diagnostic suite. Former lead at FDA's AI/ML regulatory task force.

Partner With Us in Shaping the Future of Medicine

Whether you're an institutional investor, clinical research organization, or biotech innovator, discover how Zenth Life Sciences accelerates pathways to patient impact.

View Division Report → Contact Business Development